Structure-guided envelope trimer design in HIV-1 vaccine development: a narrative review.


Journal

Journal of the International AIDS Society
ISSN: 1758-2652
Titre abrégé: J Int AIDS Soc
Pays: Switzerland
ID NLM: 101478566

Informations de publication

Date de publication:
11 2021
Historique:
received: 22 04 2021
accepted: 03 08 2021
entrez: 22 11 2021
pubmed: 23 11 2021
medline: 26 11 2021
Statut: ppublish

Résumé

The development of a human immunodeficiency virus 1 (HIV-1) vaccine remains a formidable challenge. An effective vaccine likely requires the induction of broadly neutralizing antibodies (bNAbs), which likely involves the use of native-like HIV-1 envelope (Env) trimers at some or all stages of vaccination. Development of such trimers has been very difficult, but much progress has been made in the past decade, starting with the BG505 SOSIP trimer, elucidation of its atomic structure and implementing subsequent design iterations. This progress facilitated understanding the weaknesses of the Env trimer, fuelled structure-guided HIV-1 vaccine design and assisted in the development of new vaccine designs. This review summarizes the relevant literature focusing on studies using structural biology to reveal and define HIV-1 Env sites of vulnerability; to improve Env trimers, by creating more stable versions; understanding antibody responses in preclinical vaccination studies at the atomic level; understanding the glycan shield; and to improve "on-target" antibody responses versus "off-target" responses. The authors conducted a narrative review of recently published articles that made a major contribution to HIV-1 structural biology and vaccine design efforts between the years 2000 and 2021. The field of structural biology is evolving at an unprecedented pace, where cryo-electron microscopy (cryo-EM) and X-ray crystallography provide complementary information. Resolving protein structures is necessary for defining which Env surfaces are accessible for the immune system and can be targeted by neutralizing antibodies. Recently developed techniques, such as electron microscopy-based polyclonal epitope mapping (EMPEM) are revolutionizing the way we are analysing immune responses and shed light on the immunodominant targets on new vaccine immunogens. Such information accelerates iterative vaccine design; for example, by reducing undesirable off-target responses, while improving immunogens to drive the more desirable on-target responses. Resolving high-resolution structures of the HIV-1 Env trimer was instrumental in understanding and improving recombinant HIV-1 Env trimers that mimic the structure of viral HIV-1 Env spikes. Newly emerging techniques in structural biology are aiding vaccine design efforts and improving immunogens. The role of structural biology in HIV-1 vaccine design has indeed become very prominent and is unlikely to diminish any time soon.

Identifiants

pubmed: 34806305
doi: 10.1002/jia2.25797
pmc: PMC8606863
doi:

Substances chimiques

AIDS Vaccines 0
Antibodies, Neutralizing 0
HIV Antibodies 0
env Gene Products, Human Immunodeficiency Virus 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

e25797

Subventions

Organisme : NIAID NIH HHS
ID : P01 AI110657
Pays : United States

Informations de copyright

© 2021 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of the International AIDS Society.

Références

Proc Natl Acad Sci U S A. 2017 Aug 29;114(35):E7348-E7357
pubmed: 28807998
Nat Commun. 2017 Nov 21;8(1):1655
pubmed: 29162799
AIDS. 2006 Oct 24;20(16):W13-23
pubmed: 17053344
PLoS Pathog. 2021 Feb 8;17(2):e1009257
pubmed: 33556148
Science. 2016 Mar 25;351(6280):1458-63
pubmed: 27013733
J Immunol. 2014 Sep 1;193(5):2073-86
pubmed: 25080483
J Exp Med. 2017 Sep 4;214(9):2573-2590
pubmed: 28847869
Science. 2002 Jun 28;296(5577):2354-60
pubmed: 12089434
J Virol. 2012 Aug;86(15):8319-23
pubmed: 22623764
J Biol Chem. 1990 Jun 25;265(18):10373-82
pubmed: 2355006
Structure. 2020 Aug 4;28(8):897-909.e6
pubmed: 32433992
Retrovirology. 2018 Sep 12;15(1):63
pubmed: 30208933
Science. 2013 May 10;340(6133):711-6
pubmed: 23539181
Proc Natl Acad Sci U S A. 2015 Sep 22;112(38):11947-52
pubmed: 26372963
Science. 2021 Jan 8;371(6525):
pubmed: 33214287
Cell Rep. 2018 Oct 23;25(4):893-908.e7
pubmed: 30355496
J Antimicrob Chemother. 2003 Feb;51(2):229-40
pubmed: 12562686
PLoS Pathog. 2015 Mar 25;11(3):e1004767
pubmed: 25807248
Nat Med. 2010 Jan;16(1):123-8
pubmed: 20023635
PLoS Pathog. 2016 Jan 14;12(1):e1005369
pubmed: 26766578
J Virol. 2020 Mar 17;94(7):
pubmed: 31941772
Nature. 2019 Jun;570(7762):468-473
pubmed: 31142836
J Biol Chem. 2017 Sep 22;292(38):15849-15858
pubmed: 28743743
J Virol. 2015 Dec;89(23):12189-210
pubmed: 26311893
Immunity. 2018 Mar 20;48(3):500-513.e6
pubmed: 29548671
Proc Natl Acad Sci U S A. 2016 Nov 8;113(45):E7039-E7048
pubmed: 27791170
PLoS Pathog. 2017 Sep 13;13(9):e1006614
pubmed: 28902916
J Virol. 2000 Jun;74(11):5091-100
pubmed: 10799583
Proc Natl Acad Sci U S A. 2013 Mar 12;110(11):4351-6
pubmed: 23426631
J Virol. 2010 Jun;84(11):5637-55
pubmed: 20335257
Immunity. 2019 Nov 19;51(5):915-929.e7
pubmed: 31732167
Immunity. 2018 Aug 21;49(2):235-246.e4
pubmed: 30076100
J Virol. 1993 Jan;67(1):584-8
pubmed: 8416385
Immunity. 2019 Jun 18;50(6):1513-1529.e9
pubmed: 31126879
Nat Rev Immunol. 2002 Sep;2(9):706-13
pubmed: 12209139
Proc Natl Acad Sci U S A. 1987 Nov;84(22):8120-4
pubmed: 2825177
Nat Rev Immunol. 2019 Feb;19(2):77-78
pubmed: 30560910
Curr Opin HIV AIDS. 2017 May;12(3):241-249
pubmed: 28422788
J Virol. 2020 Nov 23;94(24):
pubmed: 32999024
J Virol. 2002 Mar;76(6):2606-16
pubmed: 11861826
J Virol. 2002 Sep;76(17):8875-89
pubmed: 12163607
Cell Host Microbe. 2021 Mar 10;29(3):327-333
pubmed: 33705704
J Virol. 2015 May;89(10):5318-29
pubmed: 25740988
Nature. 2014 Oct 23;514(7523):455-61
pubmed: 25296255
Science. 2013 Dec 20;342(6165):1484-90
pubmed: 24179160
PLoS Pathog. 2020 Aug 31;16(8):e1008753
pubmed: 32866207
Nat Commun. 2018 Sep 12;9(1):3693
pubmed: 30209313
Science. 1998 Jun 19;280(5371):1884-8
pubmed: 9632381
Cell Rep. 2018 Apr 10;23(2):584-595
pubmed: 29642014
Cell Rep. 2017 Aug 22;20(8):1805-1817
pubmed: 28834745
Immunity. 2017 May 16;46(5):792-803.e3
pubmed: 28514686
Science. 2020 Sep 18;369(6510):1501-1505
pubmed: 32703906
Cell Rep. 2018 Sep 18;24(12):3324-3338.e5
pubmed: 30232012
Nature. 1998 Jun 18;393(6686):705-11
pubmed: 9641684
Immunity. 2017 Jun 20;46(6):1073-1088.e6
pubmed: 28636956
J Virol. 2013 May;87(10):5372-83
pubmed: 23468492
Immunity. 2017 May 16;46(5):804-817.e7
pubmed: 28514687
Annu Rev Immunol. 2016 May 20;34:635-59
pubmed: 27168247
Expert Rev Proteomics. 2017 Oct;14(10):881-890
pubmed: 28870097
Immunol Rev. 2017 Jan;275(1):129-144
pubmed: 28133793
Immunity. 2018 Aug 21;49(2):301-311.e5
pubmed: 30076101
Science. 2015 Jul 10;349(6244):aac4223
pubmed: 26089353
J Virol. 2000 Jan;74(2):627-43
pubmed: 10623724
Cell. 2015 Feb 12;160(4):785-797
pubmed: 25662010
Virology. 1987 Jan;156(1):171-6
pubmed: 3643678
J Virol. 2015 Oct;89(20):10383-98
pubmed: 26246566
Cell Rep. 2020 Nov 24;33(8):108432
pubmed: 33238130
Cell. 2000 Mar 3;100(5):587-97
pubmed: 10721995
Science. 2016 May 13;352(6287):828-33
pubmed: 27174988
AIDS. 2009 Nov 27;23(18):2405-14
pubmed: 19770692
Cell. 1988 Apr 8;53(1):55-67
pubmed: 2450679
Cell Rep. 2020 Mar 31;30(13):4540-4550.e3
pubmed: 32234486
Science. 2016 Mar 4;351(6277):1043-8
pubmed: 26941313
J Biol Chem. 2018 Feb 2;293(5):1688-1701
pubmed: 29222332
PLoS Pathog. 2018 Feb 23;14(2):e1006913
pubmed: 29474444
Cell Rep. 2021 Apr 6;35(1):108933
pubmed: 33826885
Science. 2013 May 31;340(6136):1113-7
pubmed: 23618766
Nat Struct Mol Biol. 2015 Jul;22(7):522-31
pubmed: 26098315
PLoS Pathog. 2013 Sep;9(9):e1003618
pubmed: 24068931
Science. 2017 Jun 2;356(6341):923-928
pubmed: 28572385
Science. 2013 Dec 20;342(6165):1477-83
pubmed: 24179159
Curr Opin HIV AIDS. 2019 Jul;14(4):302-308
pubmed: 30994503
J Biol Chem. 1995 Jun 16;270(24):14756-61
pubmed: 7782341
Proc Natl Acad Sci U S A. 2012 Nov 13;109(46):18921-5
pubmed: 23100539
Structure. 2014 Jul 8;22(7):974-84
pubmed: 24931470
Nature. 2020 Oct;586(7830):516-527
pubmed: 32967006
Nature. 2003 Mar 20;422(6929):307-12
pubmed: 12646921
J Cell Biol. 1998 Jun 15;141(6):1335-47
pubmed: 9628890
Immunity. 2016 Sep 20;45(3):483-496
pubmed: 27617678
Nat Commun. 2019 May 29;10(1):2355
pubmed: 31142746
iScience. 2020 Oct 21;23(11):101711
pubmed: 33205023
J Virol. 2015 Dec 30;90(6):2806-17
pubmed: 26719252
J Virol. 2017 Apr 28;91(10):
pubmed: 28275193
J Virol. 2018 Mar 28;92(8):
pubmed: 29367243
J Virol. 2015 Apr;89(8):4201-13
pubmed: 25631091
J Virol. 2019 Feb 5;93(4):
pubmed: 30487280
Front Immunol. 2018 May 24;9:1116
pubmed: 29881382
Immunity. 2018 May 15;48(5):855-871
pubmed: 29768174
PLoS Pathog. 2015 Jan 08;11(1):e1004570
pubmed: 25569572
PLoS Pathog. 2018 Nov 5;14(11):e1007431
pubmed: 30395637
Retrovirology. 2018 Nov 26;15(1):74
pubmed: 30477581
J Virol. 2015 Mar;89(6):3380-95
pubmed: 25589637
PLoS Pathog. 2009 May;5(5):e1000433
pubmed: 19436712
Nat Med. 1998 Jun;4(6):679-84
pubmed: 9623976
Cell Rep. 2018 Aug 21;24(8):1958-1966.e5
pubmed: 30134158
N Engl J Med. 2021 Mar 18;384(11):1003-1014
pubmed: 33730454
Trends Immunol. 2016 Mar;37(3):221-232
pubmed: 26869204
J Exp Med. 2014 Sep 22;211(10):2061-74
pubmed: 25155019
ACS Cent Sci. 2020 Oct 28;6(10):1722-1734
pubmed: 33140034
N Engl J Med. 2008 Apr 10;358(15):1590-602
pubmed: 18403767
Nat Microbiol. 2016 Nov 14;2:16199
pubmed: 27841852
Cell Rep. 2016 Aug 30;16(9):2327-38
pubmed: 27545891
Cell. 2015 Dec 17;163(7):1702-15
pubmed: 26687358
Immunity. 2017 Apr 18;46(4):690-702
pubmed: 28423342
Vaccines (Basel). 2019 Jul 29;7(3):
pubmed: 31362378
Science. 2014 Nov 7;346(6210):759-63
pubmed: 25298114
Curr Opin Struct Biol. 2017 Jun;44:125-133
pubmed: 28363124
Cell Rep. 2017 Apr 25;19(4):719-732
pubmed: 28445724
J Virol. 1991 Apr;65(4):2047-55
pubmed: 1900540
Nat Med. 2018 Jun;24(6):857-867
pubmed: 29867235
Proc Natl Acad Sci U S A. 1988 Dec;85(23):9248-52
pubmed: 3264072
Cell. 2016 Sep 8;166(6):1445-1458.e12
pubmed: 27610569
Immunity. 2018 Aug 21;49(2):288-300.e8
pubmed: 30097292
Cell Rep. 2020 Mar 17;30(11):3755-3765.e7
pubmed: 32187547
J Exp Med. 2016 Apr 4;213(4):469-81
pubmed: 27022144
Annu Rev Med. 2019 Jan 27;70:91-104
pubmed: 30691364
Cell. 2019 May 16;177(5):1153-1171.e28
pubmed: 31080066
Cell Rep. 2015 Apr 28;11(4):539-50
pubmed: 25892233
Virology. 1993 Apr;193(2):545-62
pubmed: 8460475
Curr Opin Microbiol. 2000 Oct;3(5):445-50
pubmed: 11050440
Cell. 2019 Feb 21;176(5):1026-1039.e15
pubmed: 30712865
Nat Immunol. 2018 Nov;19(11):1179-1188
pubmed: 30333615
Proc Natl Acad Sci U S A. 2020 Nov 10;117(45):28014-28025
pubmed: 33093196
Cell Rep. 2019 Apr 9;27(2):586-598.e6
pubmed: 30970260

Auteurs

Ronald Derking (R)

Department of Medical Microbiology, Amsterdam Infection & Immunity Institute, Amsterdam UMC, AMC, University of Amsterdam, Amsterdam, The Netherlands.

Rogier W Sanders (RW)

Department of Medical Microbiology, Amsterdam Infection & Immunity Institute, Amsterdam UMC, AMC, University of Amsterdam, Amsterdam, The Netherlands.
Department of Microbiology and Immunology, Weill Medical College of Cornell University, New York, New York, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH